TEM

Tempus AI, Inc.
15 filings tracked
healthcarebiotechnologyMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Tempus AI's 2026 Annual Meeting results signal a powerful vote of confidence in the company's strategic direction.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the high approval percentages, the filing reveals a governance structure that heavily favors insiders.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every TEM filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 8-K filing confirms that Tempus AI has successfully navigated its 2026 annual meeting, securing the election of its board and the approval of its auditors. While the raw numbers suggest a unified front, the underlying tension between the concentrated voting power of Class B shares and the significant volume of abstentions highlights a divide in investor sentiment. The transition to a three-year executive pay review is the most material outcome, as it shifts the governance lens from immediate accountability to long-term strategic execution.

Selected Quarter

Core Takeaway

The company has secured its leadership slate and moved to a less frequent executive compensation review, reducing short-term governance friction.

Investor Lens

Investors must weigh the benefit of a stable, long-term management mandate against the risk of reduced transparency and accountability in executive pay.

Watch Next

The next required advisory vote on the frequency of executive compensation reviews.

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.07Q2 '26 (10-Q)+0.07Q2 '26 (8-K)+0.20Q2 '26 (8-K)

Signal Timeline

12 of 46
Active Filters:Quarter: Q2 '26 (8-K)
neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change
20%
bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action
40%
neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change
20%
bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action
40%
neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change
20%
bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action
40%
neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change
20%
bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action
40%
neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change
20%
bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action
40%
neutralMay 22

Re-election of nine directors to serve until the 2027 Annual Meeting.

management change
20%
bullishMay 22

Shareholder approval of a three-year executive compensation cycle reduces short-term friction.

regulatory action
40%

Filing History

8-KMay 22, 2026
Expand Sequence

The 8-K filing confirms that Tempus AI has successfully navigated its 2026 annual meeting, securing the election of its board and the approval of its auditors. While the raw numbers suggest a unified front, the underlying tension between the concentrated voting power of Class B shares and the significant volume of abstentions highlights a divide in investor sentiment. The transition to a three-year executive pay review is the most material outcome, as it shifts the governance lens from immediate accountability to long-term strategic execution.

8-KMay 13, 2026
Expand Sequence

The 8-K filing reveals a decisive shift in Tempus AI's financing strategy, moving from traditional secured bank debt to the convertible bond market. While the immediate effect is a reduction in interest expense and the removal of secured liens, the long-term impact depends on the company's ability to scale its AI-driven healthcare analytics to support a $460 million liability. The successful upsizing of the offering suggests strong market demand, but the trade-off is a transition from cash-interest risk to equity-dilution risk. Investors must now weigh the benefit of an optimized balance sheet against the potential for a significant dilution event as the stock approaches the conversion price.

10-QMay 5, 2026
Expand Sequence

The Q1 2026 filing presents a classic high-growth, high-risk profile. Tempus AI has successfully proven that there is an aggressive appetite for its 'Intelligent Diagnostics' and data licensing products, as evidenced by the rapid top-line expansion and the securing of massive multi-year contracts. The shift toward a more positive Adjusted EBITDA suggests that the company is moving toward a sustainable scale, provided it can manage its overhead. However, the tension between rapid growth and financial stability is evident. The company is effectively racing against its own debt covenants and cash burn. The investment thesis now hinges on whether the revenue acceleration from the Ambry acquisition and the Pathos partnership can outpace the rising costs of SG&A and the looming pressure of its $1.1 billion revenue requirement. Investors are essentially betting on the company's ability to convert its data moat into a cash-flow engine before its liquidity runway or debt terms expire.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.